# A general, virus-free platform to rapidly map SARS-CoV-2 drug resistance

> **NIH NIH R21** · BROAD INSTITUTE, INC. · 2021 · $234,243

## Abstract

PROJECT SUMMARY
Development or repurposing of drugs for SARS-CoV-2 that causes COVID-19 is an active area of research,
but not much effort is being spent on developing platforms to identify mutations that may merge to the inhibitors
or neutralizing agents for these targets. Given the widespread prevalence of SARS-CoV-2 and potential abuse
of developed therapeutic agents, the emergence of such escape mutants is likely. We will develop a virus-free
platform to identify and validate escape mutants for therapeutic agents in the pipeline for SARS-CoV-2.

## Key facts

- **NIH application ID:** 10249638
- **Project number:** 1R21AI162662-01
- **Recipient organization:** BROAD INSTITUTE, INC.
- **Principal Investigator:** Amit Choudhary
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $234,243
- **Award type:** 1
- **Project period:** 2021-07-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10249638

## Citation

> US National Institutes of Health, RePORTER application 10249638, A general, virus-free platform to rapidly map SARS-CoV-2 drug resistance (1R21AI162662-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10249638. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*